Pancreatic cancer is famous as“the king of cancer”due to its high degree of malignancy,rapid course of disease development,and poor prognosis.Relevant epidemiological studies have indicated that with improvement in ...Pancreatic cancer is famous as“the king of cancer”due to its high degree of malignancy,rapid course of disease development,and poor prognosis.Relevant epidemiological studies have indicated that with improvement in people’s standard of living,the morbidity and mortality of pancreatic cancer has increased.At the same time,the disease shows an obvious upward trend worldwide.Pancreatic cancer has become a major public health problem that seriously affects the life and health of people.The present review focuses on the recent advances in interventional therapy such as transcatheter arterial infusion,radiofrequency ablation,microwave ablation,and irreversible electroporation of pancreatic cancer.展开更多
Radiomics is a hot topic in the research on customized oncology treatment,efficacy evaluation,and tumor prognosis prediction.To achieve the goal of mining the heterogeneity information within the tumor tissue,the imag...Radiomics is a hot topic in the research on customized oncology treatment,efficacy evaluation,and tumor prognosis prediction.To achieve the goal of mining the heterogeneity information within the tumor tissue,the image features concealed within the tumoral images are turned into quantifiable data features.This article primarily describes the research progress of radiomics and clinicalradiomics combined model in the prediction of efficacy,the choice of treatment modality,and survival in transarterial chemoembolization(TACE)and TACE combination therapy for hepatocellular carcinoma.展开更多
There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessar...There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world situations.In this nationwide,retrospective,cohort study,826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT(combination group,n=376)or TACE monotherapy(monotherapy group,n=450)were included from January 2018 to May 2021.The primary endpoint was progression-free survival(PFS)according to modified RECIST.The secondary outcomes included overall survival(OS),objective response rate(ORR),and safety.We performed propensity score matching approaches to reduce bias between two groups.After matching,228 pairs were included with a predominantly advanced disease population.Median PFS in combination group was 9.5 months(95%confidence interval[CI],8.4-11.0)versus 8.0 months(95%CI,6.6-9.5)(adjusted hazard ratio[HR],0.70,P=0.002).OS and ORR were also significantly higher in combination group(median OS,19.2[16.1-27.3]vs.15.7 months[13.0-20.2];adjusted HR,0.63,P=0.001;ORR,60.1%vs.32.0%;P<0.001).Grade 3/4 adverse events were observed at a rate of 15.8%and 7.5%in combination and monotherapy groups,respectively.Our results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS,OS,and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice,with an acceptable safety profile.展开更多
文摘Pancreatic cancer is famous as“the king of cancer”due to its high degree of malignancy,rapid course of disease development,and poor prognosis.Relevant epidemiological studies have indicated that with improvement in people’s standard of living,the morbidity and mortality of pancreatic cancer has increased.At the same time,the disease shows an obvious upward trend worldwide.Pancreatic cancer has become a major public health problem that seriously affects the life and health of people.The present review focuses on the recent advances in interventional therapy such as transcatheter arterial infusion,radiofrequency ablation,microwave ablation,and irreversible electroporation of pancreatic cancer.
文摘Radiomics is a hot topic in the research on customized oncology treatment,efficacy evaluation,and tumor prognosis prediction.To achieve the goal of mining the heterogeneity information within the tumor tissue,the image features concealed within the tumoral images are turned into quantifiable data features.This article primarily describes the research progress of radiomics and clinicalradiomics combined model in the prediction of efficacy,the choice of treatment modality,and survival in transarterial chemoembolization(TACE)and TACE combination therapy for hepatocellular carcinoma.
基金The study was supported by National Key Research and Development Program(2018YFA0704100,2018YFA0704104)National Natural Science Foundation of China(81827805,82130060)Jiangsu Provincial Special Program of Medical Science(BE2019750).The funding sources had no role in the writing of the report,or decision to submit the paper for publication.
文摘There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world situations.In this nationwide,retrospective,cohort study,826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT(combination group,n=376)or TACE monotherapy(monotherapy group,n=450)were included from January 2018 to May 2021.The primary endpoint was progression-free survival(PFS)according to modified RECIST.The secondary outcomes included overall survival(OS),objective response rate(ORR),and safety.We performed propensity score matching approaches to reduce bias between two groups.After matching,228 pairs were included with a predominantly advanced disease population.Median PFS in combination group was 9.5 months(95%confidence interval[CI],8.4-11.0)versus 8.0 months(95%CI,6.6-9.5)(adjusted hazard ratio[HR],0.70,P=0.002).OS and ORR were also significantly higher in combination group(median OS,19.2[16.1-27.3]vs.15.7 months[13.0-20.2];adjusted HR,0.63,P=0.001;ORR,60.1%vs.32.0%;P<0.001).Grade 3/4 adverse events were observed at a rate of 15.8%and 7.5%in combination and monotherapy groups,respectively.Our results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS,OS,and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice,with an acceptable safety profile.
